[68Ga]Ga-FAPI-46 PET/CT检测高级别尿路上皮癌淋巴结及血行转移的可行性
该先导队列纳入15例局部治疗前后的尿路上皮癌患者,行[68Ga]Ga-FAPI-46 PET/CT检测转移。原发灶SUVmax 20.8(范围8.1-27.8),淋巴结转移SUVmax 10.6(范围4.7-29.1)。4/15(26.7%)患者存在CT未发现的FAPI阳性病灶;2/15例CT可疑病灶无FAPI摄取,组织病理学排除恶性。
要点
- 原发灶SUVmax 20.8(范围8.1-27.8),淋巴结转移SUVmax 10.6(范围4.7-29.1)
- 4/15(26.7%)患者存在[68Ga]Ga-FAPI-46阳性而常规CT漏诊的病灶
- 2/15例CT可疑的双肺结节及盆腔淋巴结无FAPI摄取,组织病理学排除恶性
核心结论
- [68Ga]Ga-FAPI-46 PET在尿路上皮癌病灶中显示明显升高的摄取,该示踪剂有潜力作为转移性尿路上皮癌患者有前景的新生物标志物。
- [68Ga]Ga-FAPI-46 PET与单独CT相比可能改善转移灶的检测。
- 这些发现强烈强调需要在尿路上皮癌患者中开展更大规模的研究来探究FAPI显像。
研究设计与样本
- 先导队列研究,纳入15例局部治疗前或后的尿路上皮癌患者,行[68Ga]Ga-FAPI-46 PET/CT显像以检测转移扩散。
- 比较未受累器官的生物分布与尿路上皮癌病灶的摄取,采用标准化摄取值(SUVmean和SUVmax)测量。
- 将PET上的转移部位与增强CT上的形态学对应表现进行比较。
主要发现
- PET和/或CT共检出64个肿瘤部位。
- 摄取强度最高位于原发部位,SUVmax 20.8(范围8.1-27.8);其次为淋巴结转移,SUVmax 10.6(范围4.7-29.1)。
- 4/15(26.7%)患者存在[68Ga]Ga-FAPI-46阳性而常规CT漏诊的病灶。
- 2/15例患者CT上双肺结节及盆腔淋巴结此前评为可疑转移,但无FAPI表达升高,组织病理学排除恶性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出这些发现强烈强调需要在尿路上皮癌患者中开展更大规模的研究来探究FAPI显像。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: [68Ga]Ga-FAPI-46 is a novel positron emission tomography (PET) ligand that targets fibroblast activation protein (FAP) expression as FAP inhibitor (FAPI) and could already show promising results in several tumor entities. It could be demonstrated that an increased FAP expression correlates with tumor aggressivity in urothelial carcinoma (UC). Given the limited value of [18F]FDG in UC, [68Ga]Ga-FAPI-46 could add diagnostic information in staging and response assessment in UC. We present the first data of [68Ga]Ga-FAPI-46 PET imaging in a pilot cohort of UC patients evaluating uptake characteristics in metastases and primary tumors. METHODS: Fifteen patients with UC prior to or after local treatment underwent [68Ga]Ga-FAPI-46 PET/CT imaging for detection of metastatic spread. We compared the biodistribution in non-affected organs and tumor uptake of UC lesions by standard uptake value measurements (SUVmean and SUVmax). Additionally, metastatic sites on PET were compared to its morphological correlate on contrast-enhanced computed tomography (CT). RESULTS: Overall, 64 tumor sites were detected on PET and/or CT. The highest uptake intensity was noted at the primary site (SUVmax 20.8 (range, 8.1-27.8)) followed by lymph node metastases (SUVmax 10.6 (range, 4.7-29.1)). In 4/15 (26.7%) patients there were [68Ga]Ga-FAPI-46-positive lesions that were missed on standard routine CT imaging. On the other hand, 2/15 patients had suspicious prominent bipulmonary nodules as well as pelvic lymph nodes previously rated as suspicious for metastatic spread on CT, but without increased FAPI expression; here histopathology excluded malignancy. CONCLUSION: [68Ga]Ga-FAPI-46 PET shows distinctly elevated uptake in UC lesions. Therefore, the tracer has potential as a promising new biomarker in metastatic UC patients, as [68Ga]Ga-FAPI-46 PET might improve detection of metastatic sites compared to CT alone. These findings highly emphasize larger studies investigating FAPI imaging in UC patients.
引用
- Unterrainer LM, Lindner S, Eismann L, et al. Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. Eur J Nucl Med Mol Imaging. 2022. PMID: 35325283. doi:10.1007/s00259-022-05761-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。